ArticleThe oncologist2026
Association of immune checkpoint inhibitors with muscle mass and density in patients with melanoma.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe association between skeletal muscle wasting and immune checkpoint inhibitor (ICI) use for cancer and whether pre-treatment kidney function modifies this relationship is unknown. MATERIALS AND
methodsSingle center retrospective cohort study of patients with non-metastatic melanoma treated with or without ICIs, with a pre-treatment CT or PET-CT scan and follow-up scan within 1 year (±3 months). Paired t-tests examined the change in abdominal skeletal muscle index (SMI, cm2/height in meters) and psoas muscle density (PMD, Hounsfield units) at L3. Independent t-tests compared differences in the mean change between the ICI and non-ICI groups. Multivariable linear regression models assessed whether the change in SMI and PMD was different between groups and whether baseline estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) modified this association.
resultsThirty-six patients treated with ICIs and 41 not treated with ICIs met inclusion criteria. The non-ICI group was older (mean age ± SD = 67.0 ± 12.9 years) and more commonly male (78%) compared to the ICI group (58.9 ± 14.9 years; 50% male). The mean change in SMI was not significantly different between groups (P = 0.38). The mean change in PMD in the ICI group was -5.93 (95% confidence interval [CI] -9.58 to -2.28), which was significantly greater than the non-ICI group (-1.18, 95% CI -3.51 to 1.15), after adjusting for baseline variables (P = 0.002). Findings were not affected by baseline eGFR.
conclusionPatients treated with ICIs had a significantly higher decline in PMD as compared to patients not treated with ICIs, which was not affected by baseline eGFR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.